Compare Pfizer Inc (PFE) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Southern Copper Corp — how do they compare? Pfizer Inc trades at $27.9 (market cap $158.39B), while Southern Copper Corp trades at $209 (market cap $176.10B). The key difference: Pfizer Inc and Southern Copper Corp are close in size by market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| PFE | SCCO | |
|---|---|---|
Market Cap | $158.39B | $176.10B |
Volume | 29,869,932 | — |
Sector | Health | Basic Materials |
52-Week High | $29.02 | $219.70 |
52-Week Low | $23.60 | $102.10 |
Enterprise Value | $209.89B | $177.39B |
Dividend Yield | 6.19% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Southern Copper (SCCO) trades at $208.56, up 4.93% with strong bullish technical signals and positive earnings momentum. The company demonstrates robust fundamentals with 2025 revenue of $13.42B, net income margin of 35.87%, and consistent earnings beats. Recent news highlights copper's role in AI infrastructure demand, with SCCO benefiting from rising metal prices and a $20.5B investment plan for production growth.
SCCO presents growth potential from copper demand trends but trades at premium valuations (P/E 31.29) above analyst consensus target of $154.58. Key risks include production declines and execution challenges on expansion projects. Institutional buying activity suggests confidence in long-term prospects despite mixed analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
